Board and leadership team

Our Board members are committed to a clear, strategic vision for the Group.
  • Board
  • Audit
  • Nomination
  • Remuneration
  • Executive

Bruno Angelici

Non-Executive Chairman
Nomination Committee Chair

Appointment to the Board

Bruno Angelici was appointed to the Vectura Board in December 2013 and became Non-Executive Chairman in February 2014. Following the merger with Skyepharma in June 2016, Bruno became Chairman of the enlarged Vectura Group plc.

Experience and expertise

Bruno has an MBA (Kellogg School of Management) and business and law degrees from Reims.

Bruno’s career includes senior management roles in pharmaceutical and medical device companies. Bruno retired from AstraZeneca in 2010 as executive vice president international after a 20-year career. He was responsible for Europe, Japan, Asia Pacific, Latin America, the Middle East and Africa having originally joined as president of ICI Pharmaceuticals France. Prior to this, he was at Baxter, a US-based global supplier of medical devices. He has extensive international business leadership experience, including in the US, and brings a deep understanding to the Company of the medical device and pharmaceutical industries. Bruno was a member of the supervisory board of Wolters Kluwer NV, a global information services and publishing company. A non-executive director of Novo Nordisk A/S, a global healthcare company and world leader in diabetes care and a non-executive director of Smiths Group plc, a leading technology group.

Current external appointments

Bruno does not currently hold any other directorships.

Will Downie

Chief Executive Officer

Appointment

Will Downie was appointed Chief Executive Officer in November 2019.

Experience and Expertise

Will holds a BSc (Hons) in biochemistry from the University of Edinburgh.

Prior to joining Vectura, Will spent ten years as the senior vice president, global sales and marketing at Catalent Inc. In this role, Will led the commercial effort and had responsibility for global sales, marketing and commercial operations activities. During his tenure, he developed an outstanding track record in helping drive the long-term growth of the company, as well as positioning Catalent as one of the leading brands in the pharmaceutical services space.

He has a deep understanding of the drug development and advanced drug delivery market, and has amassed significant experience in driving sustained long-term results, as well as building performance-focused organisations and meeting customer needs on a global scale.

Prior to Catalent, Will held positions as vice president and general manager, global molecular imaging at GE Healthcare, vice president sales EMEA at Amersham Health and director of business development and commercial operations at Quintiles Innovex UK Limited. In his early career, he worked in a range of sales and marketing management positions at both Sanofi and Merck & Co.

Current external appointments

Will does not currently hold any other directorships.

Mark Bridgewater

Chief Commercial Officer

Appointment
Mark Bridgewater joined Vectura in March 2020.

Experience and expertise

Mark has more than 25 years experience in medical device and pharmaceutical B2B services. Prior to joining Vectura he was VP business development and account management for Europe and Asia at Flex in the Health Solutions business unit, a global design, engineering and manufacturing organisation. Prior to this, he was VP global business development, advanced delivery technologies at Catalent, and earlier in his career worked as head of global contract manufacturing services at Wockhardt and in various commercial roles at Patheon in Italy.

Paul Fry

Chief Financial Officer

Appointment to the Board

Paul Fry was appointed Chief Financial Officer in October 2018.

Experience and Expertise

He graduated from Oxford University in 1988 and qualified as an accountant with the Chartered Institute of Management Accountants in 1991.

Paul joined Vectura from Immunocore, a privately held T-cell receptor biotechnology company, where he was chief financial officer. Before joining Immunocore, he served as director of global finance operations at Vodafone Plc, where he was responsible for key financial controller activities and core processes as well as large transformation programmes. Prior to his role at Vodafone, he spent more than 25 years at GlaxoSmithKline (GSK), where he held a number of senior roles including head of global finance services and CFO for GSK’s Italian pharmaceutical business.

Current external appointments

In February 2020 Paul became a non-executive director of AIM-listed Avacta Group plc, a developer of Affimer® biotherapeutics and reagents, and is also Avacta’s audit committee chairman.

Thomas Werner

Senior Independent Non-Executive Director

Appointment to the Board

Dr Thomas Werner was appointed to the Board of Skyepharma as a Non-Executive Director in May 2009 and joined the Board of Vectura following the merger in June 2016.

Experience and expertise

He holds a degree in chemistry from the University of Göttingen.

Thomas has over 30 years of experience in the pharmaceutical industry, previously as senior vice president of GlaxoSmithKline, where he was managing director for Germany and also co-ordinated its European oncology business. Prior to that, he was responsible for Glaxo Wellcome Germany and Central Europe, Bristol-Myers Squibb Germany and Convatec Germany/Central Europe. He has held various non-executive positions including Riemser Pharma GmbH and New Oncology AG. Besides his business responsibilities, he has previously served for many years on the board of trustees of the Paul Ehrlich Foundation and the Robert Koch Foundation and was a director of the American Chamber of Commerce in Germany representing healthcare companies. Until October 2019 he was chairman of Fertin Pharma, a Danish medicated chewing gum company.

Current external appointments

Thomas is chairman of the investment advisory committee of the Seventure (France) Health for Life capital investment fund. He is also vice chairman of Basilea Pharmaceutica Ltd.

Per-Olof Andersson

Non-Executive Director and workforce engagement representative

Appointment to the Board

Dr Per-Olof Andersson joined the Vectura Board in April 2015.

Experience and expertise

He holds a degree in medicine from Lund University, Sweden.

Per-Olof is an expert in international research and development within the pharmaceuticals, bio-pharmaceuticals and speciality pharmaceutical industries and has considerable experience in respiratory therapeutic development. In 2011, Per-Olof retired from Almirall where he was executive director for R&D and a member of the board of directors. Prior to joining Almirall in 2006, Per-Olof had a distinguished international career at Pharmacia and Pfizer over a period of nearly 20 years. Since 2011, Per-Olof has been an independent consultant advising biotech and pharma companies. To support the 2018 Corporate Governance Code, Per-Olof has been appointed as the nominated Non-Executive Director who oversees engagement between the Board and the workforce.

Current external appointments

Per-Olof does not currently hold any other directorships.

Juliet Thompson

Non-Executive Director
Audit Committee Chair

Appointment to the Board

Juliet Thompson was appointed to the Board as a Non-Executive Director in December 2017.

Experience and expertise

Juliet has a BSc in economics and is a chartered accountant.

She has spent over 20 years actively involved in the life sciences sector working as an investment banker and strategic advisor to healthcare companies in Europe. She headed up the European healthcare team at Stifel (formerly Oriel) and prior to this was a founding partner of Code Securities, a healthcare investment banking boutique which was acquired by Nomura, later forming Nomura Code.

Current external appointments

Juliet sits on the board, and is the audit committee chair, of Novacyt S.A., a French diagnostic company whose shares are admitted to trade on AIM and Euronext. She is also a non-executive director of Organox Limited, a commercial medical technology company, spun out of Oxford University. Juliet is also a trustee of Leadership through Sport & Business, a social mobility-focused charity, trustee of the De Hann family trusts and director of their associated investment companies.

Kevin Matthews

Non-Executive Director
Remuneration Committee Chair

Appointment to the Board

Dr Kevin Matthews joined the Board in March 2019.

Experience and expertise

Kevin has more than 20 years’ experience in senior management roles in the chemical, technology and pharmaceutical sectors and has significant marketing, strategy and management expertise. Kevin is CEO of privately held speciality chemicals company Scott Bader Company Limited and was, until the end of 2018, executive chairman of Itaconix plc, an AIM-listed polymer business, having successfully led the organisation as chief executive officer. A Fellow of the Royal Society of Chemistry, Kevin has a strong technical background and has previously held CEO roles at technology companies including Isogenica, a privately held antibody drug discovery company, and Oxonica plc, an advanced materials business. Prior to this he held leadership roles in multinational chemical companies. He served as a non-executive director and remuneration committee chairman of Elementis plc, a FTSE 250 speciality chemicals business, from 2005 to 2014 and Low and Bonar, an advanced materials business from 2014 to 2019. He also served as a non-executive director of Cellectricon AB, a Swedish biotechnology company dedicated to drug discovery and research in the areas of chronic pain and neurodegenerative disease, from 2011 to 2014.

Current external appointments

Kevin is chief executive officer of the privately held speciality chemicals company Scott Bader Company Limited.

Jeanne Taylor Hecht

Non-Executive Director

Appointment to the Board

Jeanne Taylor Hecht joined the Board in December 2020. She joined the Nomination and Remuneration Committees with effect from 31 March 2021.

Experience and expertise

Jeanne is a global business executive with over 20 years’ experience leading successful teams across mature and emerging markets within the product development, pharma services and life sciences space.

Jeanne commands broad knowledge and deep expertise in the life sciences arena. She has dedicated much of her career to guiding international companies through healthy growth thoughtfully, strategically, and with unyielding integrity.

Jeanne was most recently CEO of Ora, Inc., a full-service pre-clinical and clinical ophthalmic drug and device development firm. Previously she served as chief operating officer and was a board director of Median Technologies, a clinical services imaging business. Prior to this Jeanne had a substantial career with Quintiles (later IQVIA), the world’s largest contract development services company, where she led global sales and strategic accounts.

Current external appointments

Jeanne does not currently hold any other directorships.

Jeanne Thoma

Non-Executive Director


Appointment to the Board

Jeanne Thoma joined the Board in December 2020. She joined the Audit and Remuneration Committees with effect from 31 March 2021.

Experience and expertise

Jeanne was most recently CEO and president of SPI Pharma, which provides specialist formulation and ingredient services to the pharmaceutical and nutritional industries, and is part of Associated British Foods plc. Previously she served as a senior advisor to companies within the pharmaceutical industry, and has had successful careers with Lonza where, in her last role, she was division president and executive committee member, and BASF where she served in senior key commercial roles in its pharmaceutical solutions business.

Current external appointments

Jeanne is a member of the boards of directors of ANI Pharmaceuticals Inc., an integrated speciality pharmaceutical company, and Avid Bioservices Inc., a contract development and manufacturing organisation focused on the development and cGMP manufacturing of biopharmaceutical mammalian cell culture products.

John Murphy

General Counsel and Company Secretary

Appointment

John Murphy joined Skyepharma as general counsel in March 2006 and was appointed as General Counsel and Company Secretary of Vectura in June 2016 following the merger.

Experience and expertise

John is a lawyer with extensive experience in legal and company secretarial roles in listed pharmaceutical and biotechnology companies including Medeva PLC, Celltech Group PLC and Pharmagene PLC. He is chairman of the BIA Intellectual Property Advisory Committee and a member of the EuropaBio Intellectual Property Working Group. He holds a BSc in aeronautical engineering from Bristol University and is a qualified solicitor.

Geraldine Venthoye

Chief Scientific Officer and Executive Vice President – Product Development

Appointment

Dr Geraldine Venthoye joined Vectura in June 2016 upon completion of the merger with Skyepharma PLC, where she had been executive vice president – pharmaceutical development since 2013. She joined Skyepharma as head of the inhalation business unit in September 2003.

Experience and expertise

Geraldine is a UK registered pharmacist and holds a doctorate degree in pharmaceutics from the University of London and has spent 30 years in inhaled drug delivery R&D.

Geraldine previously held senior CMC leadership and scientific roles at Inhale/Nektar Therapeutics, San Carlos, California, US, and Vandsons Research and Norton Healthcare in the UK. She completed her pre-registration clinical training at the Brompton Heart and Lung Hospital in London.

David Lescuyer

Executive Vice President – Oral Business

Appointment

David Lescuyer joined Vectura in June 2016 upon completion of the merger with Skyepharma PLC, where he had been executive vice president – oral business since April 2016.

Experience and expertise

David, a French national, holds a BSc in mechanical engineering and an MBA from HEC Paris.

David joined Skyepharma from Patheon Pharmaceuticals, where he was executive director and general manager, Patheon France, and more recently global VP, operational excellence. Prior to Patheon, David’s career included experience with Fareva, Cenexi and Catalent in senior operational and general management roles.

Joanne Hombal

Executive Vice President – Human Resources

Appointment

Joanne Hombal joined Vectura in January 2015.

Experience and expertise

Joanne has a BSc in psychology from the University of Birmingham and a postgraduate diploma in human resource management from the University of Glamorgan. She is a Chartered Member of the Institute of Personnel and Development.

Before joining Vectura, Joanne was vice president HR at Invensys Rail, with responsibility for setting and leading the people strategy for Northern Europe. She has held senior HR roles in the financial services and ICT industries and led a number of organisational development and transformation initiatives.

Antony Fitzpatrick

Executive Vice President Operations

Appointment

Antony Fitzpatrick joined Vectura in July 2017.

Experience and expertise

Antony has a first-class BSc in aeronautical engineering from Manchester University and an MSc in numerical computation from the University of Manchester Institute of Science and Technology.

Antony joined Vectura from Baxter where he had worked since 1999, having been responsible for global supply chain and also manufacturing across EMEA. His Baxter experience includes operating in both a pharma product environment and in product device and pure medical device operations. He sat on the board of GHX, the Global Healthcare Exchange, for four years prior to its sale to private equity. Before working at Baxter he worked in various manufacturing and logistics roles of increasing responsibility for Ingram Micro (IT technology), Exel Logistics, Coopers and Lybrand and Mobil Oil.

Christina Olsen

Executive Vice President – Corporate Strategy and Communications

Appointment

Christina Olsen joined Vectura in November 2016 and was appointed to the Executive Leadership Team in August 2019.

Experience and Expertise

Christina graduated from the Stockholm School of Economics with a Master’s in business and economics, majoring in finance and business strategy.

Before joining Vectura, Christina spent almost a decade in leadership roles at AstraZeneca, where her responsibilities included strategic insight to shape corporate strategy, as well as product strategy across therapeutic areas. Christina also led a corporate initiative delivering a step-change in payer capabilities. Her last role at AstraZeneca was as VP for competitive intelligence and forecasting for the global respiratory, inflammation and autoimmune portfolio.

She also worked for Chiron Corporation for three years, leading business development, and spent nine years at Boston Consulting Group, where she led and managed client projects, including biotech and top ten pharmaceutical company mergers.

Sharon Johnson

Executive Vice President - Delivery Management

Appointment

Sharon Johnson joined Vectura in February 2020.

Experience and Expertise

Sharon holds a postgraduate diploma in industrial pharmaceutical studies with distinction from Brighton University and a BSc honours degree in applied biology/microbiology from North East Surrey College of Technology. She is a Fellow of the Royal Society of Biology and a registered Qualified Person.

Sharon has more than 30 years’ experience in the pharmaceutical industry. Prior to joining Vectura she held a number of executive positions, most recently senior vice president, global quality and regulatory affairs, at Catalent, where her role was expanded to include responsibility for product development and the implementation of a project management organisation with strong governance and transparency, ensuring customer expectations of product development excellence were delivered. Earlier in her career she held the position of vice president of quality for GE Healthcare’s medical diagnostic division, and worked in roles of increasing responsibility for Baxter Healthcare and Sanofi Aventis.